Who is sponsoring NCT03652974?

NCT03652974 is sponsored by Shanghai Mental Health Center.

What drugs are being tested in NCT03652974?

Interventions in NCT03652974: sodium valproate with Clozapine, modified electroconvulsive therapy(MECT) with Clozapine, amisulpride with Clozapine, placebo with Clozapine.

What condition does NCT03652974 study?

NCT03652974 studies Schizophrenia.

Is NCT03652974 still recruiting?

NCT03652974 is currently completed. Last updated 6 September 2022.

Last reviewed 2022-09-06 · How we verify

NCT03652974

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy

Completed Phase 4 Last updated 6 September 2022

What this trial tests

Phase 4 trial testing sodium valproate with Clozapine in Schizophrenia in 145 participants. Completed in 30 August 2021.

Timeline

6 September 2018

Primary endpoint
30 August 2021

30 August 2021

Quick facts

Lead sponsor	Shanghai Mental Health Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	145
Start date	6 September 2018
Primary completion	30 August 2021
Estimated completion	30 August 2021
Sites	1 location across China

Drugs / interventions tested

sodium valproate with Clozapine — full drug profile →
modified electroconvulsive therapy(MECT) with Clozapine
amisulpride with Clozapine — full drug profile →
placebo with Clozapine — full drug profile →

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Shanghai Mental Health Center — full company profile →

Who can join

Adults 18 to 60, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, investigators designed a double-blind randomized trial to compare the efficacy and safety between sodium valproate, amisulpride and MECT combination therapy in clozapine-treated refractory schizophrenia (CTRS).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.
Zhu MH, Liu ZJ, Hu QY, Yang JY, et al · · 2022 · cited 44× · PMID 36253804 · DOI 10.1186/s40779-022-00420-0
Association of cytokines levels, psychopathology and cognition among CR-TRS patients with metabolic syndrome.
Dong Y, Zhu M, Li Y, Liu N, et al · · 2024 · cited 6× · PMID 38627438 · DOI 10.1038/s41537-024-00469-x
Amisulpride Augmentation Therapy Improves Cognitive Performance and Psychopathology in Clozapine-resistant Treatment-refractory Schizophrenia (CTRS): a 12-week Randomized, Double-blind, Placebo-controlled Trial
Li Z, Zhu M, Liu Z, Hu Q, et al · · 2022 · DOI 10.21203/rs.3.rs-1213529/v1

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Shanghai Mental Health Center trials

Trials by the same sponsor.

NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03652974 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
Last refreshed: 6 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing